Physician profile
Sammar Atassi
NPI 1396845137
$3,155.51
in general payments reported to CMS, 2019-2025
23 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $369 · 2021: $36.02 · 2022: $443 · 2023: $437 · 2024: $301 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.25 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $635.01 | 2019-2025 | |
| Amgen INC. | $403.12 | 2022-2025 | Prolia, Evenity, Prolia |
| Abbott Laboratories | $334.50 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $272.95 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $244.30 | 2019 | |
| Amarin Pharma, INC. | $205.41 | 2019-2020 | |
| Harmony Biosciences LLC | $131.29 | 2020 | |
| Lilly USA, LLC | $125.00 | 2025 | |
| Glaxosmithkline, LLC. | $118.66 | 2022-2024 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $100.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $97.74 | 2023 | Quviviq |
| Philips North America LLC | $75.60 | 2019-2020 | |
| Abbvie INC. | $64.22 | 2024 | |
| Resmed Corp | $53.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $43.33 | 2023-2024 | Breztri, Airsupra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $41.67 | 2019 | |
| Pfizer INC. | $41.22 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $40.55 | 2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $34.62 | 2023 | |
| Dexcom, INC. | $33.03 | 2023-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $22.58 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.98 | 2022 | |
| Horizon Therapeutics Plc | $17.73 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sammar Atassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.